When the human genome was fully sequenced in 2003, the prospects of genetic medicine ushered in a new era of human health. Today, scientists and drug developers have a better understanding of the genetic drivers of disease than ever before. As such, genomics stocks present a new opportunity for investors to buy into the potential future of medicine, as nearly all modern therapies rely on understanding patient genetics to be as efficient as possible.Moreover, genomics companies differ from traditional health ...